Normal prothrombin time in the presence of therapeutic levels of rivaroxaban

British Journal of Haematology

Volumn 160, Issue 6, 2013, Pages 859-861

  van Veen, Joost J ^a   Smith, Julie ^a   Kitchen, Steve ^a   Makris, Mike ^a,b  

^a Sheffield Haemophilia and Thrombosis Centre   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Anti Xa; Prothrombin time; Rivaroxaban; Thromboplastin

Indexed keywords

REAGENT; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; MEASUREMENT; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PLASMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; HUMANS; MORPHOLINES; PROTHROMBIN TIME; THIOPHENES; VENOUS THROMBOSIS;

EID: 84874716219     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12173     Document Type: Letter

References (6)

1. Baglin, T., Keeling, D. & Kitchen, S. (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. British Journal of Haematology, 159, 427-429.
2. Douxfils, J., Mullier, F., Loosen, C., Chatelain, C., Chatelain, B. & Dogne, J.M. (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thrombosis Research, 130, 956-966.
3. Hillarp, A., Baghaei, F., Fagerberg, B.I., Gustafsson, K.M., Stigendal, L., Sten-Linder, M., Strandberg, K. & Lindahl, T.L. (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. Journal of Thrombosis and Haemostasis, 9, 133-139.
4. Mueck, W., Lensing, A.W., Agnelli, G., Decousus, H., Prandoni, P. & Misselwitz, F. (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clinical Pharmacokinetics, 50, 675-686.
5. Samama, M.M., Martinoli, J.L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F. & Perzborn, E. (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis, 103, 815-825.
6. Schulman, S. & Crowther, M.A. (2012) How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood, 119, 3016-3023.